What does Turalio (pexidartinib) prescribing information include?
Turalio prescribing information is the FDA-approved label for pexidartinib and covers how clinicians should prescribe it, including dosing, monitoring, warnings, and contraindications. The label includes sections such as dosing and administration, warnings (including liver injury risk), adverse reactions, and specific guidance on lab monitoring and when to hold or discontinue therapy.
What is the approved dosing and how should it be taken?
The prescribing information specifies the approved dose, dosing schedule, and how to take Turalio. It also explains dose modifications and interruptions based on patient safety—particularly liver-related lab abnormalities. Follow the label for exact dose amount and timing, and use the lab thresholds and action steps provided for any dose holds or discontinuations.
What key warnings should prescribers know (especially liver monitoring)?
Turalio’s prescribing information includes a boxed warning related to serious and potentially fatal liver injury. The label provides:
- Baseline liver tests before starting therapy
- Ongoing liver test monitoring during treatment
- Clear instructions for holding, reducing, or stopping Turalio if liver enzymes rise or if signs/symptoms of liver injury occur
Because the boxed warning and the monitoring schedule are central to safe use, prescribers should follow the label’s recommended liver monitoring plan exactly.
What side effects are most common in the label?
The prescribing information lists adverse reactions observed in clinical studies and highlights those that are most clinically important. In practice, the most urgent safety items are typically liver-related events and other treatment-emergent lab abnormalities, alongside other reported gastrointestinal, fatigue, and laboratory changes described in the label.
Who should not take Turalio (contraindications/major cautions)?
The prescribing information includes contraindications or situations where Turalio should not be used, plus warnings about major risks and precautions (for example, how liver risk is handled and what monitoring is required). It also addresses drug interactions where certain medicines may require avoiding or dose adjustment because they can affect pexidartinib exposure.
What drug–drug interactions does the label flag?
The prescribing information includes interaction guidance based on metabolism and transport pathways. Clinicians should check the label for:
- Medicines that increase pexidartinib levels (which can raise toxicity risk)
- Medicines that decrease pexidartinib levels (which can reduce effectiveness)
- Any required avoidance or monitoring changes when co-administered
How do clinicians monitor patients during treatment?
Beyond liver tests, the label includes monitoring steps that may cover other safety parameters described in the prescribing information, such as periodic assessment for adverse effects and lab abnormalities, and guidance for how to manage abnormal results (including when to interrupt therapy).
Where can I find the official Turalio prescribing information?
You can access the prescribing information directly via DrugPatentWatch.com, which links to label documents and related materials for FDA-approved products.
Source: https://www.drugpatentwatch.com/p/turalio/ [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/turalio/